Everus Construction Group (NYSE: ECG) today reported financial results for the fourth quarter and full year 2024.

Learn more about the fiscal 2025 first-quarter financial results of Maximus and CEO Bruce Caswell's update on the company's AI development efforts.

Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...

Stifel analysts maintained their Hold rating on Supernus Pharmaceuticals (NASDAQ:SUPN) shares, with a steady price target of $38.00. Trading near its 52-week high with a strong 30% gain over the past ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Supernus ...

Alphabet Inc. (GOOG) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $39.25, changing hands for $39.41/share. When a stock ...

ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...

Earnings, adjusted for one-time gains ... A live webcast with presentation sl Supernus Pharmaceuticals Inc (SUPN) reports a 32% revenue increase, driven by Qelbree and Gocovri, while advancing ...

Adani Energy, Ultratech Cement, and United Spirits will be the focus on January 23, 2025, as earnings announcements by top Indian companies for the quarter ended December 2024 continue.